cytoprotectants
antacids
H2-receptor antagonists
PPIs
Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole Dexlansoprazole
antacids AE
cautions: kidney insufficiency, drug interactions (chelation w/ fluoroquinolone, tetracyclines)
antacids MOA
work locally within the GI lumen to neutralize acid
quick relief of symptoms, but duration of action short (a few hours)
bismuth compounds
bismuth subsalicylate
AE
(pepto-bismol)
sucralfate
sulfated polysaccharide + AlOH3
uses: acid-peptic ulcer disease (adjunctive or alt agent), stress ulcer prophylaxis
sucralfate AE
sucralfate use in kidney insufficiency is dangerous why
accumulation of Al 3+ can occur
misoprostol
prevention of ulcers w/ NSAID use
prostaglandin E analog
misoprostol
AE
- inc uterine contractility (termination/induction)
H2 antagonists
H2 antagonist uses
H2A should be dose adjusted for
kidney insufficiency
H2A adverse effects
gynecomastia (men)
galactorrhea (women)
cimetidine (H2A)
H2A drug interactions
drugs req an acidic environment (atazanavir, itraconazole)
cimetidine (H2A) =inhibitor of CYP-450 (phenytoin, theophylline, warfarin)
PPI
MOA
IRREVERSIBLY bind to and inactivate H/K-ATPASE
PPI
pharmacokinetics
plasma half life 1-2hr
onset 2-4 days
duration of effect 24-48 hr
PPI
uses
PPI
AE
anti-platelet + PPI = interaction?
clopidogrel (prodrug) –> active form includes 2 steps req p450 enz (2C19) which is inhibited by PPI